Eric Chen Quin Lam

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Helle Linnebjerg, Eric Chen Quin Lam, Mary Seger et al. · Diabetes Care · 2015 · 95 citations

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Robert R. Henry, Sunder Mudaliar, Theodore P. Ciaraldi et al. · Diabetes Care · 2014 · 58 citations · Full text

Hypertriglyceridemia in Lecithin-cholesterol Acyltransferase-deficient Mice Is Associated with Hepatic Overproduction of Triglycerides, Increased Lipogenesis, and Improved Glucose Tolerance

Dominic S. Ng, Chunhui Xie, Graham F. Maguire et al. · Journal of Biological Chemistry · 2004 · 44 citations · Full text

Duration of action of two insulin glargine products, <scp>LY2963016</scp> insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

Helle Linnebjerg, Eric Chen Quin Lam, Xin Zhang et al. · Diabetes Obesity and Metabolism · 2016 · 30 citations · Full text

Reduced peripheral activity leading to hepato‐preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

Sunder Mudaliar, Robert R. Henry, Theodore P. Ciaraldi et al. · Diabetes Obesity and Metabolism · 2016 · 19 citations · Full text